<DOC>
	<DOCNO>NCT03055793</DOCNO>
	<brief_summary>The great efficacy combination therapy lead development fix combination device simultaneously carry glucocorticosteroid LABA ( eg stable combination fluticasone-salmeterol , budesonide-formoterol ) . Fixed combination easier use patient , potentially increase compliance , ensure LABA always accompany glycocorticosteroeides1 . From available combination combination budesonide-formoterol use maintenance therapy relief symptom due rapid onset action formoterol compare salmeterol . Both component budesonide-formoterol combination administer demand contribute strengthen protection severe exacerbation patient receive combination therapy maintenance , enable improvement asthma control relatively low dos ICS .</brief_summary>
	<brief_title>Quality Life Assessment Greek asthmatIc Patients Treated With Fixed Dose Combination Budesonide / Formoterol Clinical Practice</brief_title>
	<detailed_description>This prospective observational study Greek population approximately 2,500 patient suffer asthma , aim collect characteristic patient select obtain inhaled combination budesonide formoterol fumarate dihydrate portion 100 / 6mcg , 200 / 6mcg , 400/12 mcg ( Pulmoton® ) , collect data quality life inhale combination Elpenhaler® device . Data collect period three month patient diagnose asthma adequately control inhaled corticosteroid 'as need ' inhaled beta2-agonists short-acting patient already adequately control inhaled corticosteroid long-acting beta2-agonists . Data collect period one ( 1 ) three ( 3 ) month ( ± 2 week ) initiation treatment inhaled combination include ACQ checklist questionnaire mini AQLQ , questionnaire FSI 10 , data exist comorbidities .</detailed_description>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<mesh_term>Budesonide , Formoterol Fumarate Drug Combination</mesh_term>
	<criteria>Men woman patient asthma 18 year Compliant treatment Compliant study procedure Signed consent form write study information Patients Asthma start treatment inhaled combination budesonide / formoterol dose 100 / 6mcg , 200 / 6mcg , 400/12 mcg , Elpenhaler® device may include study . Under current SPC , drug Pulmoton® indicate regular treatment asthma , wherein administration combination ( inhaled corticosteroid longaction beta2agonist ) appropriate , namely patient : patient adequately control inhaled corticosteroid 'as need ' inhaled beta2agonists shortacting already adequately control inhaled corticosteroid longacting beta2agonists Note : Pulmoton® 100/6 microgram / dose suitable patient severe asthma . Men woman Asthma patient 18 year Noncompliance treatment Noncompliance study procedure Do sign patient consent Incorrect use inhale therapy Patients COPD ( stage ) Patients already receive combination ICS / LABA entry study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>